These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 38539518)
21. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients. Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065 [TBL] [Abstract][Full Text] [Related]
22. [Application of next-generation sequencing in detection of BRCA1/2 and homologous recombination repair pathway multi-genes germline mutation and correlation analysis]. Chen YL; Zhuo ZL; Liu C; Xie F; Yang ZY; Liu PF; Wang S; Zhao XT Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Mar; 56(3):302-311. PubMed ID: 35381651 [No Abstract] [Full Text] [Related]
23. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma. Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199 [TBL] [Abstract][Full Text] [Related]
24. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer. Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965 [TBL] [Abstract][Full Text] [Related]
25. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer. Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296 [TBL] [Abstract][Full Text] [Related]
26. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer. Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812 [TBL] [Abstract][Full Text] [Related]
28. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer. Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036 [TBL] [Abstract][Full Text] [Related]
29. Detection of Rodriguez BJ; Córdoba GD; Aranda AG; Álvarez M; Vicioso L; Pérez CL; Hernando C; Bermejo B; Parreño AJ; Lluch A; Ryder MB; Jones FS; Fredebohm J; Holtrup F; Queipo-Ortuño MI; Alba E J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31394872 [TBL] [Abstract][Full Text] [Related]
30. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC). Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349 [TBL] [Abstract][Full Text] [Related]
31. Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study. Chi Y; Su M; Zhou D; Zheng F; Zhang B; Qiang L; Ren G; Song L; Bu B; Fang S; Yu B; Zhou J; Yu J; Li H Elife; 2023 Nov; 12():. PubMed ID: 37929934 [TBL] [Abstract][Full Text] [Related]
32. Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer Patients. Sun MY; Lin FQ; Chen LJ; Li H; Lin WQ; Du HY; Yang XX; Li M Curr Oncol; 2021 Jun; 28(4):2326-2336. PubMed ID: 34202466 [TBL] [Abstract][Full Text] [Related]
33. Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy. Yang W; Zou J; Li Y; Liu R; Yan Z; Chen S; Zhao X; Guo W; Huang M; Li W; Zhu X; Chen Z Front Oncol; 2022; 12():830816. PubMed ID: 35280779 [TBL] [Abstract][Full Text] [Related]
34. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761 [TBL] [Abstract][Full Text] [Related]
35. Detection of TP53 gene mutation in blood of breast cancer patients based on circulating tumor DNA and its application in prognosis. Lu Q; Wei L; Cai S; Zhang Z; Zhang L Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):200-206. PubMed ID: 38015519 [TBL] [Abstract][Full Text] [Related]
36. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer. Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q Front Oncol; 2021; 11():751106. PubMed ID: 35273907 [TBL] [Abstract][Full Text] [Related]
37. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing. Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147 [TBL] [Abstract][Full Text] [Related]
38. The fate of BRCA1-related germline mutations in triple-negative breast tumors. Kotoula V; Fostira F; Papadopoulou K; Apostolou P; Tsolaki E; Lazaridis G; Manoussou K; Zagouri F; Pectasides D; Vlachos I; Tikas I; Lakis S; Konstantopoulou I; Pentheroudakis G; Gogas H; Papakostas P; Christodoulou C; Bafaloukos D; Razis E; Karavasilis V; Bamias C; Yannoukakos D; Fountzilas G Am J Cancer Res; 2017; 7(1):98-114. PubMed ID: 28123851 [TBL] [Abstract][Full Text] [Related]
39. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma. Guan S; Deng G; Sun J; Han Q; Lv Y; Xue T; Ding L; Yang T; Qian N; Dai G Front Oncol; 2022; 12():926260. PubMed ID: 36081557 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]